Thromb Haemost 1996; 75(05): 712-716
DOI: 10.1055/s-0038-1650353
Original Article
Schattauer GmbH Stuttgart

Hypercoagulable State in Patients with Takayasu’s Arteritis

Hiroshi Akazawa
The Department of Cardiology, Jichi Medical School, Minamikawachi, Tochigi, Japan
,
Uichi Ikeda
The Department of Cardiology, Jichi Medical School, Minamikawachi, Tochigi, Japan
,
Keiji Yamamoto
The Department of Cardiology, Jichi Medical School, Minamikawachi, Tochigi, Japan
,
Toshio Kuroda
The Department of Cardiology, Jichi Medical School, Minamikawachi, Tochigi, Japan
,
Kazuyuki Shimada
The Department of Cardiology, Jichi Medical School, Minamikawachi, Tochigi, Japan
› Author Affiliations
Further Information

Publication History

Received 30 October 1995

Accepted after revision 10 January 1996

Publication Date:
10 July 2018 (online)

Summary

Thrombus formation is recognized pathologically in the affected arteries and is supposed to play a major role in the pathogenesis of Takayasu’s arteritis; however, hemostatic conditions in this disorder have not been elucidated fully. We determined plasma levels of molecular markers for platelet activity (platelet factor 4; PF4, β-throm-boglobulin; βTG), thrombotic status (thrombin-antithrombin III complex; TAT, fibrinopeptide A; FPA), fibrinolytic status (plasmin-β2-plasmin inhibitor complex; PIC, D-dimer), and endothelial injury (von Willebrand factor antigen; vWF:Ag, thrombomodulin; TM) in 30 patients with Takayasu’s arteritis and in 20 age-matched control subjects. Plasma levels of PF4, βTG, TAT, FPA and D-dimer, but not PIC, in patients with Takayasu’s arteritis were substantially higher than those in normal control subjects. The levels of these markers were not different between the active and inactive stages of the disease. Plasma levels of vWF:Ag in patients with Takayasu’s arteritis did not differ significantly from those in normal subjects, and plasma levels of TM were significantly lower than those in normal subjects. In patients with Takayasu’s arteritis, platelet and coagulation activities are significantly increased, leading to hypercoagulable state and thrombus formation, although there is little, if any, endothelial damage.

 
  • References

  • 1 Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE. Takayasu’s arteritis. Clinical study of 107 cases. Am Heart J 1977; 93: 94-103
  • 2 Nasu T. Pathology of pulseless disease: A systemic study and critical review of twenty-one autopsy cases reported in Japan. Angiology 1962; 14: 225-242
  • 3 Uyama O, Nagatsuka K, Nakamura M, Matsumoto M, Fujisawa A, Yoneda S, Kimura K, Abe H. Plasma concentrations of 6-keto-prostaglandin Fla in patients with hypertension, cerebrovascular disease or Takayasu’s arteritis. Thromb Res 1982; 25: 71-79
  • 4 Numano F, Shimokado K, Kishi Y, Nishiyama K, Turkoglu C, Yajima M, Numano F, Maezawa H. Changes in the plasma levels of thromboxane B2 and cyclic nucleotides in patients with Takayasu disease. Jpn Circ J 1982; 46: 16-20
  • 5 Numano F, Maruyama Y, Koyama T, Numano F. Antiaggregative aspirin dosage at the affected vessel wall. Angiology 1986; 37: 695-701
  • 6 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350
  • 7 Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med 1993; 117: 71-77
  • 8 Yamamoto K, Ikeda U, Seino Y, Mito H, Fujikawa H, Sekiguchi H, Shimada K. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol 1995; 25: 107-112
  • 9 Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995; 25: 1634-1640
  • 10 Ishikawa K. Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu’s arteriopathy. J Am Coll Cardiol 1988; 12: 964-972
  • 11 Ueno A, Awane Y, Wakabayashi A, Shimizu K. Successfully operated obliterative brachiocephalic arteritis (Takayasu) associated with the elongated coarctation. Jpn Heart J 1967; 8: 538-544
  • 12 Ishikawa K, Matsuura S. Occlusive thromboaortopathy (Takayasu’s disease) and pregnancy: clinical course and management of 33 pregnancies and deliveries. Am J Cardiol 1982; 50: 1293-1300
  • 13 Niewiarowski S, Thomas DP. Platelet factor 4 and adenosine diphosphate release during human platelet aggregation. Nature 1969; 222: 1269-1270
  • 14 Moore S, Pepper DS, Cash JD. The isolation and characterisation of a platelet-specific β-globulin (β-thromboglobulin) and the detection of antiurokinase and antiplasmin released from thrombin-aggregated washed human platelets. Biochim Biophys Acta 1975; 379: 360-369
  • 15 Fisher M, Levine PH, Fullerton AL, Forsberg A, Duffy CP, Hoogasian JJ, Drachman DA. Marker proteins of platelet activation in patients with cerebrovascular disease. Arch Neurol 1982; 39: 692-695
  • 16 Nossel HL, Wasser J, Kaplan KL, LaGamma KS, Yudelman I, Canfield RE. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline. J Clin Invest 1979; 64: 1371-1378
  • 17 Al-Mondhiry H. Beta-thromboglobulin and platelet-factor 4 in patients with cancer: correlation with the stage of disease and the effect of chemotherapy. Am J Hematol 1983; 14: 105-111
  • 18 Voisin PJ, Rousselle D, Streiff F, Debry G, Stoltz JF, Drouin P. Reduction of beta-thromboglobulin levels in diabetics controlled by artificial pancreas. Metabolism 1983; 32: 138-141
  • 19 Hoogendijk EMG, ten Cate JW, Ludlam CA, Bruin T. No effect of aspirin on β-thromboglobulin plasma levels in healthy volunteers. Thromb Res 1980; 19: 257-262
  • 20 Carrieri P, Orefice G, Indaco A. No effect of acetylsalicylic acid on β-thromboglobulin and platelet factor 4 plasma levels in patients with transient ischaemic attacks. Stroke 1986; 17: 1153-1155
  • 21 Takehara K, Igarashi A, Ishibashi Y. Dipyridamole specificially decreases platelet-derived growth factor release from platelets. Pharmacology 1990; 40: 150-156
  • 22 Ugarte M, de Teresa E, Lorenz P, Marin MC, de Artaza M, Martin-Judez V. Intracoronary platelet activation in ischemic heart disease: effects of ticlopidine. Am Heart J 1985; 109: 738-743
  • 23 Berglund U, von Schenck H, Wallentin L. Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985; 54: 808-812
  • 24 Bettelheim FR. The clotting of fibrinogen: II. Fractionation of peptide material liberated. Biochim Biophys Acta 1956; 19: 121-130
  • 25 Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1097
  • 26 van Deventer SJH, Biiller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526
  • 27 Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-α2-anti-plasmin complex in human plasma: application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost 1986; 56: 124-127
  • 28 Graeff H, Hafter R. Detection and relevance of crosslinked fibrin derivatives in blood. Semin Thromb Hemost 1982; 8: 57-68
  • 29 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 1973; 52: 2757-2764
  • 30 Brinkhous KM, Sultzer DL, Reddick RL, Griggs TR. Elevated plasma von Willebrand factor (vWF) levels as an index of acute endothelial injury: use of a hypotonic injury model in rats. Fed Proc 1980; 39: 630 (Abstract)
  • 31 Nusinow SR, Federici AB, Zimmerman TS, Curd JG. Increased von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum 1984; 27: 1405-1410
  • 32 Giustolisi R, Musso R, Cacciola E, Cacciola RR, Russo M, Petralito A. Abnormal plasma levels of factor VUI/von Willebrand factor complex in myocardial infarction: expression of acute phase reaction or index of vascular endothelium damage?. Thromb Haemost 1984; 51: 408
  • 33 Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257: 859-854
  • 34 Tomura S, Nakamura Y, Deguchi F, Chida Y, Ohno Y, Kodama S, Hayashi T, Suzuki K, Marumo F. Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy. Thromb Res 1990; 58: 413-419
  • 35 Wada H, Ohiwa M, Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992; 39: 20-24
  • 36 Karmochkine M, Cacoub P, Dorent R, Piette JC, Boffa MC, Gandjbakhch I, Godeau P. Thrombomoduline et hypertension arterielle pulmonaire. Rev Med Interne 1992; 13: S366 (Abstract)